Wegovy pill, the first oral GLP-1 for weight loss, is FDA-approved for reducing cardiovascular risks in adults. Phase III OASIS 4 trial showed 16.6% mean weight loss with oral semaglutide, ...
Novo Nordisk wins FDA approval for Wegovy in a pill, introducing first oral GLP-1 option for obesity
After ushering in a new era of obesity treatment with its GLP-1 medicine Wegovy earlier in the decade, Novo Nordisk is making history again with the first FDA approval of a GLP-1 pill for weight loss.
Inflation in November fell to 2.7%, the Bureau of Labor Statistics said Thursday, a positive sign for consumers on its face. However, November’s data was collected later than normal. The released ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback